13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Page 4 of 8 – SEC Filing

CUSIP No. 86627R102
1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Lansdowne Developed Markets Master Fund Limited
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
WC
5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEMS 2(d) OR 2(e)

[_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7. SOLE VOTING POWER
0
8. SHARED VOTING POWER
19,060,500(2)
9. SOLE DISPOSITIVE POWER
0
10. SHARED DISPOSITIVE POWER
19,060,500(2)
11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

PERSON

19,060,500(2)
12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

CERTAIN SHARES

[_]
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
25.91%
14. TYPE OF REPORTING PERSON
CO

__________________

(2) The 19,060,500 Ordinary Shares beneficially owned
consist of 11,077,170 Ordinary Shares and 1,596,666 American Depositary Shares, which may be exchanged for Ordinary Shares at a
1:5 ratio.

Follow Summit Therapeutics Inc. (NASDAQ:SMMT)